Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer
Yükleniyor...
Tarih
2007
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: In this non-randomized study we aimed to assess the efficacy of the addition of low molecular weight heparin (LMWH) to gemcitabine (GEM) plus cisplatinum (CDDP) combination chemotherapy on survival by prevention of thromboembolic complications in patients with advanced pancreatic cancer (APC). Patients and Methods: Between November 1999 and February 2004, 69 consecutive patients with APC were treated with GEM (800 Mo,/M2, day 1, day 8) plus CDDP (35 mg/m(2), day 1, day 8) every 21 days +/- LMWH (nadroparine calcium, 2,850 IU/day until disease progression). Ten out of 35 patients in LMWH group and 10 out of 34 patients in chemotherapy alone group had primary inoperable locally advanced disease and the rest of the patients had metastatic disease. Results: Total response rate was 58.8% (11.7% CR) for the patients treated with LMWH and 12.1% for those treated without LMWH (P = 0.0001). LMWH group had a better median time to progression (TTP) and survival when compared to control group (7.3 vs. 4.0 months, P = 0.0001; 13.0 vs. 5.5 months, P = 0.0001). The toxicity was similar and acceptable in both groups. Conclusion: Addition of LMWH to GEM plus CDDP combination significantly improved the response and survival in patients with APC and the current schedule deserves to be tested in phase III trials. J. Surg. Oncol. 2007;95:507-512. (C) 2006 Wiley-Liss, Inc.
Açıklama
38th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 18-21, 2002 -- ORLANDO, FL
Anahtar Kelimeler
Advanced pancreatic carcinoma, Low Molecular weight heparin, Cisplatin, Gemcitabine, Nadroparine
Kaynak
Journal of Surgical Oncology
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
95
Sayı
6
Künye
İçli, F., Akbulut, H., Utkan, G., Yalçın, B., Dinçol, D., Işıkdoğan, A. ve diğerleri. (2007). Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. Journal of Surgical Oncology, 95(6), 507-512.
